Form 4: Harvard Bioscience Director Awarded 110,000 RSUs

Stephen J. DeNelsky, a director at Harvard Bioscience, received an award of 110,000 restricted stock units vesting in 2026.

Summary

• Stephen J. DeNelsky, a Director of Harvard Bioscience, Inc. (HBIO), was awarded 110,000 shares of Common Stock.
• The transaction date for this award was September 5, 2025.
• The shares were acquired at a price of $0.00 per share, indicating an equity award rather than a purchase.
• Following this transaction, Mr. DeNelsky beneficially owns 110,000 shares directly.
• The award represents 110,000 restricted stock units (RSUs) that are scheduled to fully vest on September 5, 2026.

Sentiment

Score: 7

Explanation: The award of restricted stock units to a director is generally a positive signal, as it aligns the director's financial interests with the long-term performance of the company and shareholder value. It represents a commitment from the director and a standard practice for incentivizing leadership.

Positives

• The award of restricted stock units to a director aligns management's long-term interests with those of shareholders, promoting sustained company performance.
• Equity-based compensation is a common incentive mechanism to retain and motivate key personnel.

Future Outlook

The 110,000 restricted stock units awarded to Director Stephen J. DeNelsky are scheduled to fully vest on September 5, 2026, indicating a future milestone for this equity compensation.

Industry Context

The award of restricted stock units to a director is a standard practice in the life sciences and biotechnology industry, used to incentivize long-term commitment and align leadership interests with shareholder value creation. This type of compensation is a common component of executive and director remuneration packages across publicly traded companies.

Comparison to Industry Standards

• Restricted stock unit awards are a widely adopted form of equity compensation for directors and executives in publicly traded companies, including those in the life sciences sector, such as Thermo Fisher Scientific Inc. (TMO) or Danaher Corporation (DHR), which frequently utilize similar long-term incentive plans to retain talent and align interests.

Related Party Transactions

• The award of 110,000 restricted stock units to Stephen J. DeNelsky, a Director of Harvard Bioscience, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The award aligns the director's interests with long-term shareholder value, potentially leading to more focused strategic decisions aimed at increasing stock price.
• Management/Directors: Provides a long-term incentive for the director, linking their personal wealth to the company's performance.

Next Steps

• The 110,000 restricted stock units will vest on September 5, 2026, at which point they will convert into shares of common stock.

Key Dates

Keywords

Harvard Bioscience, HBIO, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Award, Beneficial Ownership